LSK Global PS-Chemon Concludes MOU to Maximize

                                            Joint Research and Development Competencies of New Drugs

- South Korea’s leading CRO LSK Global PS signsMOU with Korea’s first privatenon-clincal tirals research organization ChemOn

- Two companies’ joined expertise is todemonstrate maximized competence in the healthcare field

[November 9, 2017] South Korea’s leadingcontract research organization (CRO) LSK Global PS (LSK Global Pharma ServicesCo., Ltd.) announced on November 8^th to have signed a Memorandum of Understanding(MOU) with Korea’s first private non-clincal tirals research organization ChemOn(ChemOn Inc.) for systematic joint research and product development fields suchas pharmaceuticals, medical devices and health-functional foods. Through theMOU, the two companies aims to provide a one-stop service from non-clinical tothe whole process of clinical trials in product development of new drugs toincrease efficiency and collaborate for the purpose of providing more specializedservices.

This MOU by LSK Global PS and ChemOn includes the followings: sharingopportunities to provide services related to clinical and non-clinical trialsin products such as new drugs,  consortiumof product joint research as well as development such as new drugs and otherbusiness activities deemed necessary for cooperation between the two parties . Thetwo companies’ cooperation are expected to maximize efficiency and serviceexpansion based on ChemOn’s expertise in non-clinical trial together with LSKGlobal PS’ expertise in clinical trials in joint research and development ofnew drugs and other products.

In addition, the two companies are expected to increase the success rate ofjoint research and development of products such as new drugs by allocatingtasks based on the MOU and minimizing the time and cost in selecting newcandidate materials or when introducing new technologies from 3^rdparties.

# # #